Yes, selinexor, marketed under the brand name Xpovio, is FDA approved. The U.S. Food and Drug Administration (FDA) granted approval for selinexor on an accelerated basis on July 3, 2019. This approval is based on the medication's ability to meet an unmet medical need in patients with specific types of cancer.
Selinexor is an oral medication used in combination with other drugs to treat multiple myeloma and certain types of diffuse large B-cell lymphoma (DLBCL) in adults. It is a selective inhibitor of nuclear export (SINE) compound, classified under miscellaneous antineoplastics.
Selinexor is available in oral tablet forms with various dosing schedules, including once or twice weekly administration, depending on the specific regimen and combination with other medications. Dosages must be carefully followed as prescribed by a healthcare provider.
Selinexor can cause a range of side effects, some of which can be serious or fatal. Common side effects include:
Serious side effects may include blurred vision, severe nausea, loss of appetite, confusion, symptoms of sepsis, signs of infection, and low sodium levels.
Selinexor can interact with other medications, including prescription and over-the-counter drugs, vitamins, and herbal products. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.
Selinexor (Xpovio) received FDA approval on July 3, 2019, for treating multiple myeloma and diffuse large B-cell lymphoma. As with all medications, it is crucial to follow the prescribed dosage and administration instructions and to be aware of potential side effects and interactions with other drugs.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!